|Institutional Source||Beutler Lab|
|Gene Name||oncostatin M|
|Is this an essential gene?||Non essential (E-score: 0.000)|
|Stock #||R6621 (G1)|
|Chromosomal Location||4236420-4241026 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||T to A at 4239541 bp|
|Amino Acid Change||Aspartic acid to Glutamic Acid at position 108 (D108E)|
|Ref Sequence||ENSEMBL: ENSMUSP00000074708 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000075221]|
|Predicted Effect||probably benign
AA Change: D108E
PolyPhen 2 Score 0.029 (Sensitivity: 0.95; Specificity: 0.82)
AA Change: D108E
|Predicted Effect||noncoding transcript
|Coding Region Coverage||
|Validation Efficiency||100% (36/36)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a member of the leukemia inhibitory factor/oncostatin-M (LIF/OSM) family of proteins. The encoded preproprotein is proteolytically processed to generate the mature protein. This protein is a secreted cytokine and growth regulator that inhibits the proliferation of a number of tumor cell lines. This protein also regulates the production of other cytokines, including interleukin 6, granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in endothelial cells. This gene and the related gene, leukemia inhibitory factor, also present on chromosome 22, may have resulted from the duplication of a common ancestral gene. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016]
PHENOTYPE: Homozygous mutant mice display decreased noxious responses in models of acute thermal, mechanical, chemical, and visceral pain. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Osm||
(F):5'- GTTTTAAAGGCAGCCAAGACGG -3'
(R):5'- ACATCTGGTGTTGTAGTGGACC -3'
(F):5'- AGCCAAGACGGGTTTCTCTG -3'
(R):5'- CGTGAGGCCCCAGAGTCTG -3'